Skip to main content
    S

    Spero Therapeutics Inc (SPRO)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.90
    -0.05 (-4.77%)

    Market Cap: $58.26M

    Last updated: Nov 17, 2026 at 4:11 PM ET

    Spero Therapeutics Inc (SPRO) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Spero Therapeutics (SPRO) has a market cap of $58.26M. It holds $107.93M more cash than debt, 185.26% of its market cap. It kept -71.02% of revenue as net income over the last 12 months.

    Total Valuation

    Market Cap$58.26M
    Latest price (Nov 17, 2026)$0.90

    Key Dates

    The next earnings report is expected on Mar 24, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 24, 2027 (expected)
    Last Earnings DateNov 12, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.45% in the quarter ended Sep 30, 2026 and grew 3.72% a year over 2 years.

    Shares Outstanding58.23M
    Shares Change (YoY)+3.46%
    Shares Change (QoQ)+0.45%
    Share Count Growth (2Y CAGR)+3.72%

    Valuation Ratios

    Sales and book value multiples are 1.3x and 67.2x.

    P/E Ratio10.6x
    P/S Ratio1.3x
    Forward P/S194.2x
    P/B Ratio67.2x

    Valuation history and multiples

    Price Statistics

    The stock is down 62.60% over 52 weeks and trades 20.35% below its 50-day average.

    Beta (1Y)1.53
    52-Week Change-62.60%
    1-Month Change-19.53%
    3-Month Change-26.72%
    6-Month Change-65.20%
    5-Year Change-93.96%
    Total Return (1Y)-62.60%
    Total Return (3Y CAGR)-8.84%
    Total Return (5Y CAGR)-44.04%
    Max Drawdown (1Y)-69.75%
    Max Drawdown (3Y)-70.35%
    Sharpe Ratio (1Y)-1.54
    Correlation with SPY (1Y)0.32
    50-Day Average$1.13
    200-Day Average$1.90
    52-Week Range$0.90 to $3.08
    RSI (14 Days)31.6
    Average Volume (20 Days)338.16K

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 1.92x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio1.92x
    Quick Ratio1.92x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on equity is -3778.87% over the last 12 months, against a 5-year average of -55.12%.

    Return on Equity (ROE)-3778.87%
    Return on Assets (ROA)-26.82%
    Return on Capital Employed (ROCE)-52.72%
    ROE (5Y Average)-55.12%
    ROA (5Y Average)-25.35%
    ROIC (5Y Average)10.38%
    Asset Turnover0.51x

    Scores

    SPRO has an Altman Z-Score of -6.12, in the distress zone below 1.81, and a Piotroski F-Score of 4 of 9, in the average band of 3 to 7.

    Altman Z-Score-6.12
    Altman Z ZoneDistress
    Piotroski F-Score4 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $41.55M over the last 12 months is up 2.48% from the 12 months before.

    Revenue$41.55M
    Revenue Growth (YoY)+2.48%
    Gross Profit$41.55M
    Operating Income-$27.97M
    Pretax Income-$29.25M
    Net Income-$29.51M
    EBIT-$27.98M
    Reported EPS (TTM)$0.09

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 0.71% of the $110.03M in total assets.

    Cash and Equivalents$107.93M
    Total Debt$0
    Net Cash$107.93M
    Net Cash Per Share$1.85
    Working Capital$52.27M
    Shareholder Equity$781.00K
    Book Value Per Share$0.01
    Total Assets$110.03M
    Total Liabilities$109.25M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow-$40.45M
    FCF Per Share-$0.69

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -67.31%.

    Gross Margin100.00%
    Operating Margin-67.31%
    Pretax Margin-70.39%
    Net Margin-71.02%
    EBIT Margin-67.32%

    Growth

    Revenue grew 7.68% a year over 3 years.

    Revenue Growth (3Y CAGR)+7.68%
    Revenue Growth (5Y CAGR)+48.25%
    Book Value Per Share Growth (2Y CAGR)-29.72%
    Tangible Book Per Share Growth (2Y CAGR)-29.72%

    Revenue and profit by year

    Dividends and Yields

    SPRO does not pay a dividend.

    Earnings Yield9.43%
    Shareholder Yield0.00%

    Peer Position

    Against 5 similar companies, SPRO has the 5th highest P/S.

    P/S Ratio1.3x vs 2.9x median
    Revenue Growth (Trailing 4 Quarters, YoY)+2.48% vs -48.86% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at -99.55% a year over the next fiscal year.

    Revenue Growth Forecast (1Y CAGR)-99.55%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About SPRO

    What is SPRO's market cap?

    Spero Therapeutics has a market cap of $58.26M.

    What is SPRO's P/E ratio?

    Spero Therapeutics has a trailing P/E ratio of 10.6x.

    How many shares of SPRO are outstanding?

    Spero Therapeutics has 58.23M shares outstanding. The count is up 3.46% from a year earlier.

    Does SPRO pay a dividend?

    No. Spero Therapeutics does not pay a dividend.

    How much debt does SPRO have?

    Spero Therapeutics has $0 of total debt and $107.93M of cash and equivalents, a net cash position of $107.93M.